SEC Form 4 · accession 0001104659-15-051898
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan S Leff
Director
Period of report
Jul 16, 2015
Accepted (ET)
Jul 20, 2015 · 3:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F1,F2 | $17.49 | Jul 16, 2015 | A | 11,475 | A | — | Jul 16, 2025 | Common Stock | 11,475 | 11,475 | D |
Explanation of responses
- F1The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- F2The shares shall vest in 36 equal monthly installments measured commencing from June 17, 2015.
- F3Inapplicable.